首頁 > 市場調查報告書 > 醫療設備

生技設備

肌酸酐檢測市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按測試類型、產品、樣品、最終用戶、地區、競爭細分

市場調查報告書

商品編碼

1355176

肌酸酐檢測市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按測試類型、產品、樣品、最終用戶、地區、競爭細分

Creatinine Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Test Type, By Product, By Sample, By End User, By Region, Competition

出版日期: 2023年09月05日 | 出版商:

TechSci Research | 英文 208 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

The Global Creatinine Assay Market was valued at USD 360.12 million in 2022 and is expected to exhibit robust growth in the forecast period, with a CAGR of 6.6% through 2028. The measurement of creatinine is a vital test conducted to evaluate renal function in the human身體.肌酸酐是肌肉產生能量後產生的一種化合物，保留在體內。評估血液和尿液樣本中的肌酸酐水平可以確定腎臟濾除肌酸酐時的腎臟狀態。對於成人，肌酸酐測量的正常範圍是每分升血液 0.5 至 1.2 毫克。肌酸酐水平升高表示腎臟狀況不健康。腎臟疾病的盛行率不斷上升，特別是在發展中國家，由於生活條件不利，導致對肌酸酐測量測試的需求不斷成長。此外，市場成長是由測試套件和試劑的成本效益和廣泛可用性所推動的。

主要市場促進因素

腎臟相關健康問題的發生率不斷上升

市場概況
預測期	2018-2028
2022 年市場規模	54025萬美元
2028 年市場規模	77395萬美元
2023-2028 年複合年成長率	6.04%
成長最快的細分市場	試劑
最大的市場	北美洲

腎臟疾病，包括慢性腎臟病 (CKD)，對全球死亡率有重大影響。早期診斷和適當的治療對於預防併發症起著至關重要的作用。肌酸酐測試方法用於評估腎功能。市場參與者優先生產高品質的產品，以滿足不斷成長的需求。此外，該領域研究活動的增加有助於全球市場的擴大。越來越多的人被診斷出患有腎臟相關疾病，導致對肌酸酐檢測以評估腎功能和監測疾病進展的需求更高。對於腎病患者來說，定期監測腎功能，包括肌酸酐水平是必要的。這種持續監測推動了頻繁肌酸酐測試的需要。醫院、診所和醫療機構通常會進行肌酸酐測定，以評估患有腎臟相關問題或正在接受可能影響腎功能的治療的患者的腎功能。由於需要快速獲得結果和立即做出臨床決策，從而能夠及時管理患者，在重症監護環境中擴大採用床邊肌酸酐檢測。在製藥業，肌酸酐測定用於臨床前和臨床研究，以評估新藥對腎功能和潛在腎毒性的影響。人們對腎臟健康的認知不斷增強，導致常規健康檢查的增加，其中包括肌酸酐檢測，以檢測腎功能障礙的早期跡象，從而推動了全球肌酸酐檢測市場的發展。

老年人口增加

老年人口的增加以及隨後與年齡相關的健康狀況的增加極大地推動了對肌酸酐測定的需求。隨著年齡的成長，腎臟相關疾病和腎功能受損的風險往往會增加。老年人群的腎功能評估和腎臟健康監測在很大程度上依賴肌酸酐測定的關鍵作用。腎臟自然發生與年齡相關的變化，導致腎功能下降和腎小球濾過率（GFR）下降。檢測老年人的腎功能障礙至關重要，肌酸酐測定是此過程中的基本工具。老年人經常需要多種藥物來治療慢性病，這強調了腎功能在清除體內藥物方面的重要性。透過促進適當的藥物劑量調整，肌酸酐測定可幫助醫療保健提供者預防老年患者的潛在毒性和不良反應。定期肌酸酐檢測可以及早發現老年人的腎臟疾病，從而及時進行干預和管理，以防止疾病進展和併發症。隨著老年人口的持續成長，對肌酸酐測定的需求預計將保持在較高水平。確保腎臟健康和早期發現腎臟疾病對於管理老年族群的健康和福祉至關重要，使肌酸酐檢測成為老年護理和醫學中不可或缺的工具。

主要市場挑戰

對肌酸酐檢測方法認知有限：

許多患者可能缺乏肌酸酐檢測在評估腎功能及其對整體健康影響的重要性的認知。不同的醫療機構可能採用不同的肌酸酐測試方法，導致患者和醫療保健提供者對結果的準確性和可靠性產生困惑。在某些情況下，醫療保健提供者可能會優先考慮其他健康參數而不是肌酸酐測試，這可能會錯過腎功能障礙的早期跡象。公共衛生措施和宣傳活動可能無法充分解決腎臟健康和肌酸酐檢測在促進整體健康方面的重要性。

肌酸酐檢測試劑盒在體外診斷 (IVD) 中的利用不足：

IVD 中肌酸酐檢測試劑盒的可用性或使用有限可能會導致醫療保健提供者和患者獲得這些診斷測試的機會受到限制。這可能會導致腎臟相關疾病的診斷不足或延遲診斷。肌酸酐檢測試劑盒的使用有限也可能導致不同醫療機構的肌酸酐檢測缺乏標準化。標準化對於確保一致和可靠的結果至關重要，而缺乏廣泛使用的檢測試劑盒可能會阻礙此過程。醫療保健提供者可能會探索評估腎功能的替代診斷方法，例如即時檢測或其他生物標記物，這可能會轉移對傳統肌酸酐測定的需求。肌酸酐檢測試劑盒的製造商可能會遇到對其產品的需求減少，從而影響他們的收入和獲利能力。反過來，這可能會影響他們投資研發或改進檢測試劑盒的能力。

主要市場趨勢

即時護理測試：

POCT 可以在患者床邊、門診診所甚至偏遠或資源有限的地區進行。它消除了患者前往集中實驗室進行肌酸酐檢測的需要，從而提高了診斷服務的可近性。對於患有慢性腎病（CKD）或正在接受可能影響腎功能的治療的患者，POCT可以頻繁、方便地監測肌酸酐水平，從而能夠及時調整治療計劃。在遠距醫療或遠距醫療保健環境中，肌酸酐 POCT 可以遠端監測腎功能，促進護理的連續性和個人化治療計劃。此外，POCT 可以減少多次訪問或樣品運輸到集中實驗室的需要，從而節省成本。

新興市場不斷成長的需求：

隨著新興市場醫療保健服務的改善，對具有成本效益且方便用戶使用的肌酸酐試劑盒的需求預計將會增加。製造商可能會專注於為這些市場開發負擔得起且可靠的解決方案。新興市場醫療基礎設施的改善和醫療服務範圍的擴大意味著更多的人可以接受定期健康檢查，包括腎功能評估。人們越來越認知到預防性醫療保健的重要性，鼓勵個人定期進行篩檢，包括肌酸酐檢測，以發現腎功能障礙的早期跡象。政府為提高醫療保健可及性和品質而採取的舉措，以及解決非傳染性疾病 (NCD) 的努力，可以進一步推動對肌酸酐檢測的需求。

細分市場洞察

對測試類型的見解：

根據測試類型，Jaffe 的動力學方法成為市場的主導部分。這主要是因為它是測量肌酸酐最古老、最傳統的方法，因而擁有最大的市場佔有率。 Jaffe 法採用簡單的比色測定，肌酸酐在鹼性條件下與苦味酸反應，形成紅橙色髮色團。顏色變化的強度與肌酸酐的濃度成正比，使其成為方便的測量方法。 Jaffe 方法在臨床實驗室中被廣泛接受和標準化，使其成為肌酸酐檢測的參考方法。它在臨床試驗和研究中的廣泛應用進一步確立了其可信度。其他佔據該細分市場重要佔有率的因素包括 Jaffe 動力學測試套件的廣泛可用性和成本效益。

對樣本的見解：

其中，血液樣本佔據肌酸酐檢測試劑盒市場的主導地位。由於血液樣本的可及性，該細分市場佔有最大的市場佔有率。血液通常用於肌酸酐檢測，因為肌酸酐是肌肉代謝的廢物，會釋放到血流中，隨後被腎臟過濾。血液中肌酸酐的濃度保持相對穩定，可作為腎功能的指標，特別是腎小球濾過率（GFR）。然而，由於擴大使用尿液樣本進行肌酸酐測量，特別是在腎功能評估中，尿液樣本部分正在經歷快速成長。尿液肌酸酐通常用於計算肌酸酐清除率，這是估計 GFR 的另一種方法。然而，值得注意的是，尿液肌酸酐測定通常與血液肌酸酐測量結合使用，進一步確定了樣本部分中血液樣本的主導地位。

區域見解：

預計北美市場在預測期內將佔據重要的收入佔有率。這可歸因於腎衰竭和慢性腎臟疾病的盛行率不斷上升，以及肌酸酐檢測方法的進步和該地區醫療基礎設施的改善。此外，有利的報銷政策預計將進一步推動市場成長。 2022 年，在主要參與者實施各種策略以擴大收入機會和地理影響力的推動下，亞太市場出現了快速成長。由於人們對肌酸酐檢測方法的認知不斷提高、患有糖尿病和腎臟疾病等慢性病的老年人口不斷增加，以及醫療保健領域的研發活動不斷增加等因素，亞太地區市場的收入正在快速成長。

主要市場參與者

雅培實驗室
賽默飛世爾科技
默克公司
奎德爾公司
細胞生物實驗室公司
建威生物科技
朗道實驗室有限公司
艾康實驗室
諾瓦生物醫學
希森美康印度列兵。有限公司

可用的客製化：

全球肌酸酐測定市場報告以及給定的市場資料，技術科學研究根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

其他市場參與者（最多五個）的詳細分析和概況分析。

The Global Creatinine Assay Market was valued at USD 360.12 million in 2022 and is expected to exhibit robust growth in the forecast period, with a CAGR of 6.6% through 2028. The measurement of creatinine is a vital test conducted to evaluate renal function in the human body. Creatinine, a chemical compound produced after muscle energy production, remains in the body. Assessing creatinine levels in blood and urine samples enables the determination of kidney status as the kidneys filter out creatinine. In adults, the normal range for creatinine measurement is 0.5 to 1.2 milligrams per deciliter of blood. Elevated creatinine levels indicate unhealthy kidney conditions. The increasing prevalence of kidney diseases, particularly in developing countries due to unfavorable living conditions, has resulted in a growing demand for creatinine measurement tests. Moreover, the market growth is driven by the cost-effectiveness and widespread availability of test kits and reagents.

Key Market Drivers

Growing Incidence of Kidney-Related Health Problems

Market Overview
Forecast Period	2018-2028
Market Size 2022	USD 540.25 Million
Market Size 2028	USD 773.95 Million
CAGR 2023-2028	6.04%
Fastest Growing Segment	Reagents
Largest Market	North America

Kidney disorders, including chronic kidney disease (CKD), contribute significantly to global mortality rates. Early diagnosis and appropriate treatment play a crucial role in preventing complications. Creatinine testing methods are utilized to evaluate renal functionality. Market players prioritize the production of high-quality products to meet the rising demand. Furthermore, increased research activities in this field contribute to the expansion of the global market. The growing number of individuals diagnosed with kidney-related diseases has led to a higher demand for creatinine testing to assess kidney function and monitor disease progression. Regular monitoring of kidney function, including creatinine levels, is necessary for patients with kidney diseases. This continuous monitoring drives the need for frequent creatinine testing. Creatinine assays are routinely performed in hospitals, clinics, and healthcare facilities to evaluate kidney function in patients admitted with kidney-related issues or undergoing treatments that may impact kidney function. The adoption of point-of-care creatinine testing has increased in critical care settings due to the need for rapid results and immediate clinical decision-making, which enables timely patient management. In the pharmaceutical industry, creatinine assays are used in pre-clinical and clinical research to assess the impact of new drugs on kidney function and potential nephrotoxicity. The growing awareness about kidney health has led to an increase in routine health check-ups that include creatinine testing to detect early signs of kidney dysfunction, thereby boosting the global creatinine assay market.

The growing demand for rapid diagnostic techniques and procedures to measure creatinine levels in blood and urine is a key driver of market growth. The prevalence of diabetes, which has a negative impact on kidney health, along with the increasing incidence of chronic kidney disorders among the aging population and the rising number of patients with kidney cancer, glomerulonephritis, and renal failures, among others, are fueling the need for rapid diagnostic procedures to measure creatinine levels. Creatinine, an endogenous waste product formed during the breakdown of creatine found in muscles, is used by clinical laboratories to assess health and kidney function by testing glomerular filtration rate (GFR) and blood urea nitrogen (BUN).

Technological advancements in creatinine detection have led to the development of a biosensor construction based on a single-mode fiber-multicore fiber-multimode fiber-single-mode fiber (SMFMCF-MMF-SMF) configuration. This construction is characterized by simplicity, portability, and high sensitivity. To enhance the generation of strong evanescent waves, the diameter of the sensing probe has been reduced to 90m using chemical etching. The sensor probe is functionalized with graphene oxide (GO), gold nanoparticles (AuNPs), molybdenum disulfide nanoparticles (MoS2-NPs), and the creatininase (CA) enzyme. Fiber optic localized surface plasmon resonance (LSPR) is employed to assess the concentration of creatinine. Two-dimensional (2D) materials, such as GO and MoS2-NPs, are used to enhance biocompatibility, while CA increases the probe's specificity. The use of evanescent waves (EWs) enhances the impact of AuNPs on LSPR.

Moreover, high-resolution transmission electron microscopy (HR-TEM) and UV-visible spectroscopy are utilized to analyze and evaluate the shape and absorption spectra of nanoparticles (NPs). Scanning electron microscopy (SEM) is used to characterize NPs adsorbed on the surface of the fiber probe. The performance of the sensor probe is evaluated in terms of reusability, repeatability, stability, selectivity, and pH tests. The suggested sensor exhibits a sensitivity of 0.0025 nm/M, a standard deviation of 0.107, and a detection limit of 128.4m within a linear detection range of 0 - 2000m. Based on these findings, significant market growth is anticipated in the forecast period.

Increasing Geriatric Population

The increasing geriatric population and the subsequent rise in age-related health conditions significantly drive the demand for creatinine assay. With advancing age, the risk of kidney-related diseases and impairments in kidney function tends to escalate. The assessment of kidney function and monitoring renal health in the elderly population heavily relies on the crucial role of the creatinine assay. Age-related changes naturally occur in the kidneys, leading to reduced kidney function and a decline in the glomerular filtration rate (GFR). Detecting kidney dysfunction in older adults is vital, and the creatinine assay serves as a fundamental tool in this process. Elderly individuals often require multiple medications to manage chronic conditions, emphasizing the importance of kidney function in clearing drugs from the body. By facilitating appropriate drug dosage adjustments, creatinine assays help healthcare providers prevent potential toxicity and adverse effects in older patients. Regular creatinine testing enables early detection of kidney disease in older adults, allowing for timely interventions and management to prevent disease progression and complications. As the geriatric population continues to grow, the demand for creatinine assay is expected to remain high. Ensuring kidney health and early detection of kidney diseases will be paramount in managing the health and well-being of the elderly population, making creatinine testing an indispensable tool in geriatric care and medicine.

Key Market Challenges

Limited awareness of creatinine testing methods:

Many patients may lack awareness of the importance of creatinine testing in evaluating kidney function and its impact on overall health. Different healthcare settings may employ various methods for creatinine testing, leading to confusion among patients and healthcare providers regarding the accuracy and reliability of results. In some cases, healthcare providers may prioritize other health parameters over creatinine testing, potentially missing early signs of kidney dysfunction. Public health initiatives and awareness campaigns may not adequately address the significance of kidney health and creatinine testing in promoting overall well-being.

Underutilization of creatinine assay kits in in vitro diagnostics (IVD):

Limited availability or usage of creatinine assay kits in IVD can result in restricted access to these diagnostic tests for healthcare providers and patients. This could potentially lead to underdiagnosis or delayed diagnosis of kidney-related conditions. Limited usage of creatinine assay kits may also contribute to a lack of standardization in creatinine testing across different healthcare settings. Standardization is crucial for ensuring consistent and reliable results, and the absence of widely used assay kits can hinder this process. Healthcare providers may explore alternative diagnostic methods for assessing kidney function, such as point-of-care tests or other biomarkers, potentially diverting demand away from traditional creatinine assays. Manufacturers of creatinine assay kits might experience reduced demand for their products, affecting their revenue and profitability. This, in turn, could impact their ability to invest in research and development or improvements to their assay kits.

Key Market Trends

Point-of-Care Testing:

POCT can be conducted at the patient's bedside, in outpatient clinics, or even in remote or resource-limited areas. It eliminates the need for patients to visit a centralized laboratory for creatinine testing, thereby enhancing accessibility to diagnostic services. For patients with chronic kidney disease (CKD) or those undergoing treatments that may affect kidney function, POCT allows for frequent and convenient monitoring of creatinine levels, enabling timely adjustments to treatment plans. In telemedicine or remote healthcare settings, POCT of creatinine enables remote monitoring of kidney function, promoting continuity of care and personalized treatment plans. Furthermore, POCT can lead to cost savings by reducing the need for multiple visits or sample transportation to centralized laboratories.

Growing Demand in Emerging Markets:

As access to healthcare improves in emerging markets, the demand for cost-effective and user-friendly creatinine kits is expected to increase. Manufacturers are likely to focus on developing affordable and reliable solutions for these markets. The improvement of healthcare infrastructure and expanded access to medical services in emerging markets mean that more individuals can undergo regular health check-ups, including assessments of kidney function. Growing awareness about the importance of preventive healthcare is encouraging individuals to seek regular screenings, including creatinine testing, to detect early signs of kidney dysfunction. Government initiatives to enhance healthcare access and quality, along with efforts to address non-communicable diseases (NCDs), can further drive the demand for creatinine assays.

Segmental Insights

Insights on Test Types:

Based on the test types, Jaffe's Kinetic method emerged as the dominant segment in the market. This is primarily due to its status as the oldest and most traditional method for measuring creatinine, resulting in the largest market share. The Jaffe method utilizes a simple colorimetric assay, where creatinine reacts with picric acid under alkaline conditions, forming a red-orange chromophore. The intensity of the color change is directly proportional to the concentration of creatinine, making it a convenient measurement method. The Jaffe method is widely accepted and standardized in clinical laboratories, making it a reference method for creatinine testing. Its credibility is further established by its extensive use in clinical trials and research studies. Other contributing factors to the significant share of this segment include the wide availability and cost-effectiveness of Jaffe's Kinetic Test Kits.

Insights on Sample:

Among the sample, blood samples dominate the Creatinine Assay Kits Market. This segment holds the largest market share due to the accessibility of blood samples. Blood is commonly used for creatinine testing because creatinine, a waste product of muscle metabolism, is released into the bloodstream and subsequently filtered by the kidneys. The concentration of creatinine in blood remains relatively stable and serves as an indicator of kidney function, specifically the glomerular filtration rate (GFR). However, the urine sample segment is experiencing rapid growth, driven by the increasing use of urine samples for creatinine measurements, particularly in the assessment of kidney function. Urine creatinine is often used to calculate creatinine clearance, an additional method for estimating GFR. However, it is important to note that urine creatinine assays are typically used in conjunction with blood creatinine measurements, further establishing the dominance of blood samples in the sample segment.

Regional Insights:

The North America market is projected to hold a significant revenue share during the forecast period. This can be attributed to the increasing prevalence of renal failure and chronic kidney diseases, as well as advancements in creatinine testing methods and improved healthcare infrastructure in the region. Furthermore, favorable reimbursement policies are expected to further drive market growth. In 2022, the Asia Pacific market witnessed a rapid growth rate, fueled by major players implementing various strategies to expand their revenue opportunities and geographic presence. The market in the Asia Pacific region is experiencing rapid revenue growth due to factors such as growing awareness about creatinine testing methods, a rising geriatric population with chronic diseases like diabetes and kidney disorders, and increased research and development activities in the healthcare sector.

Key Market Players

Abbott Laboratories
Thermo Fisher Scientific
Merck KGaA
Quidel Corporation
Cell Biolabs, Inc.
Genway Biotech
Randox Laboratories Ltd.
ACON Laboratories
Nova Biomedical
Sysmex India Pvt. Ltd.

Report Scope:

In this report, the Global Creatinine Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Creatinine Assay Market, By Test Type:

Jaffe Kinetic Method
Enzymatic Method

Creatinine Assay Market, By Product:

Reagents
Kits

Creatinine Assay Market, By Sample:

Blood/Serum
Urine

Creatinine Assay Market, By End User:

Hospitals
Diagnostic Laboratories

Creatinine Assay Market, By Region:

North America
- United States
- Canada
- Mexico

Europe
- France
- United Kingdom
- Italy
- Germany
- Spain

Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea

South America
- Brazil
- Argentina
- Colombia

Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Creatinine Assay Market.

Available Customizations:

Global Creatinine Assay market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Creatinine Assay Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type (Jaffe Kinetic Method, Enzymatic Method)
- 5.2.2. By Product (Reagents, Kits)
- 5.2.3. By Sample (Blood/Serum, Urine)
- 5.2.4. By End User (Hospitals, Diagnostic Laboratories)
- 5.2.5. By Region
- 5.2.6. By Company (2022)
5.3. Market Map

6. North America Creatinine Assay Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type
- 6.2.2. By Product
- 6.2.3. By Sample
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Creatinine Assay Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Test Type
    - 6.3.1.2.2. By Product
    - 6.3.1.2.3. By Sample
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Creatinine Assay Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Test Type
    - 6.3.2.2.2. By Product
    - 6.3.2.2.3. By Sample
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Creatinine Assay Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Test Type
    - 6.3.3.2.2. By Product
    - 6.3.3.2.3. By Sample
    - 6.3.3.2.4. By End User

7. Europe Creatinine Assay Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type
- 7.2.2. By Product
- 7.2.3. By Sample
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Creatinine Assay Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Test Type
    - 7.3.1.2.2. By Product
    - 7.3.1.2.3. By Sample
    - 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Creatinine Assay Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Test Type
    - 7.3.2.2.2. By Product
    - 7.3.2.2.3. By Sample
    - 7.3.2.2.4. By End User
- 7.3.3. Italy Creatinine Assay Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Test Type
    - 7.3.3.2.2. By Product
    - 7.3.3.2.3. By Sample
    - 7.3.3.2.4. By End User
- 7.3.4. France Creatinine Assay Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Test Type
    - 7.3.4.2.2. By Product
    - 7.3.4.2.3. By Sample
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Creatinine Assay Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Test Type
    - 7.3.5.2.2. By Product
    - 7.3.5.2.3. By Sample
    - 7.3.5.2.4. By End User

8. Asia-Pacific Creatinine Assay Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type
- 8.2.2. By Product
- 8.2.3. By Sample
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Creatinine Assay Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Test Type
    - 8.3.1.2.2. By Product
    - 8.3.1.2.3. By Sample
    - 8.3.1.2.4. By End User
- 8.3.2. India Creatinine Assay Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Test Type
    - 8.3.2.2.2. By Product
    - 8.3.2.2.3. By Sample
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Creatinine Assay Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Test Type
    - 8.3.3.2.2. By Product
    - 8.3.3.2.3. By Sample
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Creatinine Assay Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Test Type
    - 8.3.4.2.2. By Product
    - 8.3.4.2.3. By Sample
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Creatinine Assay Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Test Type
    - 8.3.5.2.2. By Product
    - 8.3.5.2.3. By Sample
    - 8.3.5.2.4. By End User

9. South America Creatinine Assay Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Test Type
- 9.2.2. By Product
- 9.2.3. By Sample
- 9.2.4. By End User
- 9.2.5. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Creatinine Assay Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Test Type
    - 9.3.1.2.2. By Product
    - 9.3.1.2.3. By Sample
    - 9.3.1.2.4. By End User
- 9.3.2. Argentina Creatinine Assay Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Test Type
    - 9.3.2.2.2. By Product
    - 9.3.2.2.3. By Sample
    - 9.3.2.2.4. By End User
- 9.3.3. Colombia Creatinine Assay Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Test Type
    - 9.3.3.2.2. By Product
    - 9.3.3.2.3. By Sample
    - 9.3.3.2.4. By End User

10. Middle East and Africa Creatinine Assay Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Test Type
- 10.2.2. By Product
- 10.2.3. By Sample
- 10.2.4. By End User
- 10.2.5. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Creatinine Assay Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Test Type
    - 10.3.1.2.2. By Product
    - 10.3.1.2.3. By Sample
    - 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Creatinine Assay Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Test Type
    - 10.3.2.2.2. By Product
    - 10.3.2.2.3. By Sample
    - 10.3.2.2.4. By End User
- 10.3.3. UAE Creatinine Assay Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Test Type
    - 10.3.3.2.2. By Product
    - 10.3.3.2.3. By Sample
    - 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Creatinine Assay Market: SWOT Analysis

14. Competitive Landscape

14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Key Personnel
14.5. SWOT Analysis
- 14.5.1. Abbott Laboratories
- 14.5.2. Thermo Fisher Scientific
- 14.5.3. Merck KGaA
- 14.5.4. Quidel Corporation
- 14.5.5. Cell Biolabs, Inc.
- 14.5.6. Genway Biotech
- 14.5.7. Randox Laboratories Ltd.
- 14.5.8. ACON Laboratories
- 14.5.9. Nova Biomedical
- 14.5.10. Sysmex India Pvt. Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

肌酸酐測量市場 - 預測 2024-2029

肌酐檢測試劑盒市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

血肌酐檢測套件的全球市場

血肌酐檢測的全球市場(2022年～2029年)

FAQ

肌酸酐檢測市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按測試類型、產品、樣品、最終用戶、地區、競爭細分

Creatinine Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Test Type, By Product, By Sample, By End User, By Region, Competition

主要市場促進因素

腎臟相關健康問題的發生率不斷上升

老年人口增加

主要市場挑戰

對肌酸酐檢測方法認知有限：

肌酸酐檢測試劑盒在體外診斷 (IVD) 中的利用不足：

主要市場趨勢

即時護理測試：

新興市場不斷成長的需求：

細分市場洞察

對測試類型的見解：

對樣本的見解：

區域見解：

主要市場參與者

可用的客製化：

公司資訊

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球肌酸酐檢測市場展望

第 6 章：北美肌酸酐測定市場前景

第 7 章：歐洲肌酸酐測定市場前景

第 8 章：亞太地區肌酸酐檢測市場展望

第 9 章：南美洲肌酸酐測定市場前景

第 10 章：中東和非洲肌酸酐檢測市場展望

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球肌酸酐檢測市場：SWOT 分析

第14章：競爭格局

第 15 章：策略建議

第 16 章：關於我們與免責聲明

Key Market Drivers

Growing Incidence of Kidney-Related Health Problems

Increasing Geriatric Population

Key Market Challenges

Limited awareness of creatinine testing methods:

Underutilization of creatinine assay kits in in vitro diagnostics (IVD):

Key Market Trends

Point-of-Care Testing:

Growing Demand in Emerging Markets:

Segmental Insights

Insights on Test Types:

Insights on Sample:

Regional Insights:

Key Market Players

Report Scope:

Creatinine Assay Market, By Test Type:

Creatinine Assay Market, By Product:

Creatinine Assay Market, By Sample:

Creatinine Assay Market, By End User:

Creatinine Assay Market, By Region:

Competitive Landscape

Available Customizations:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Creatinine Assay Market Outlook

6. North America Creatinine Assay Market Outlook

7. Europe Creatinine Assay Market Outlook

8. Asia-Pacific Creatinine Assay Market Outlook

9. South America Creatinine Assay Market Outlook

10. Middle East and Africa Creatinine Assay Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Global Creatinine Assay Market: SWOT Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer